WW International Inc specializes in weight management and providing clinical solutions in the United States... Show more
WW International, the operator of WeightWatchers, is executing a deliberate transition from a legacy behavioral-subscription diet business toward an integrated "weight health" ecosystem. The strategy combines medication access and telehealth clinical care through its WeightWatchers Clinic and Med+ tier with behavioral coaching, nutrition support, and community programming. Management frames this as a differentiation against prescription-only telehealth rivals, arguing that combining GLP-1 therapy with structured support produces measurably better outcomes.
The company's competitive edge rests on brand equity, clinical data, and a dual-subscription model designed to capture both lifestyle dieters and medical weight-loss patients. The clinical offering carries an average revenue per user (ARPU) more than four times that of the behavioral tier, so the mix shift toward clinical and higher-value Core+ memberships supports margin quality even as headline subscriber counts shrink. However, the company faces intense competition from established telehealth platforms, large retailers, and do-it-yourself nutrition tools, and its overall market share in weight management remains contested as GLP-1 demand reshapes the category.
Several forward-looking events could shape investor sentiment. The most immediate is the company's upcoming quarterly earnings release, which will test whether clinical subscriber growth can continue offsetting behavioral declines and whether the Core+ tier sustains its return to growth. Management has reaffirmed full-year 2026 revenue guidance of $620 million to $635 million and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) expectations, making each quarterly print a checkpoint on credibility.
Product and partnership catalysts are also material. The company has expanded access to newer oral GLP-1 medications, added a subscription pricing model intended to lower self-pay costs for Wegovy, and deepened integrations with LillyDirect and Sam's Club. These initiatives could widen the addressable member pool and improve member acquisition economics. A collaboration with Google Health Enterprise and Fitbit signals a push toward technology-enabled employer programs.
On the analyst front, consensus has turned cautiously constructive. A poll of four analysts reported by S&P Global places the consensus rating at "Buy" with an average 12-month price target of roughly $27.50, spanning a range of about $20 to $35. Northland Capital Markets initiated coverage with an "Outperform" rating and a $25 target in October 2026, while Morgan Stanley has maintained a more conservative "Hold" rating with a $20 target. This dispersion reflects genuine disagreement about the pace of the clinical transition.
The company's trajectory is tightly linked to the broader obesity-care market. GLP-1 adoption is expanding rapidly, driven by falling effective prices, new oral formulations, and widening insurance and Medicare coverage. Management has described this as a "permanent structural shift," and the company is positioned to benefit from greater medication access through its clinical tier. At the same time, GLP-1s act as a substitute for traditional behavioral programs, pressuring the legacy subscriber base.
Macroeconomic conditions matter on two fronts. Consumer discretionary spending and employment trends influence willingness to pay for subscription services, while employer and payer willingness to subsidize weight-health benefits affects the business-to-business (B2B) channel. Interest rates and capital-market conditions also influence the cost of servicing the company's remaining term loan and the valuation multiple applied to a still-unprofitable equity. The regulatory environment — including Food and Drug Administration (FDA) guidance on compounded medications and evolving Medicare coverage policy — adds another layer of sensitivity.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, exchange-traded fund (ETF), or other asset may trend bullish, bearish, or sideways over the next week or month. The platform is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. Its searchable prediction categories, historical context, and alert-oriented functionality make it a practical resource for monitoring names like WW alongside broader market signals. For traders seeking a data-driven edge in fast-moving conditions, exploring the Trend Prediction Engine can add a useful layer of forward-looking analysis.
Looking into 2026 and beyond, WeightWatchers' outlook hinges on whether clinical revenue growth can eventually offset structural declines in the behavioral segment. Management expects clinical revenue to reach roughly 25% to 30% of the total in 2026, up from about 10% in 2024, suggesting the mix shift is still in its early-to-middle innings. Sustaining that pace will require continued GLP-1 market expansion, effective member acquisition, and strong retention through the clinically intensive Med+ offering.
Long-term themes include expansion into adjacent health areas such as menopause and women's health, international telehealth partnerships, and a growing employer-and-payer distribution channel. The technology rebuild — a unified app with AI-powered tools, food-photo recognition, and personalized insights — is central to improving conversion and cross-selling. Margin sustainability will depend on balancing clinician-heavy service costs against the higher ARPU of clinical memberships.
Competitive threats remain significant. Large retailers, telehealth providers, and digital health platforms are all competing for GLP-1-adjacent revenue, and the company's still-narrow profitability leaves limited room for error. Activist investor Galloway Capital Partners has publicly argued the stock is undervalued and urged leadership and capital-allocation actions, adding a potential catalyst for strategic change. Consensus analyst expectations, which cluster around a "Buy" rating with a wide target range, reflect both the upside potential of a successful clinical transformation and the genuine uncertainty surrounding execution.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MYCI | 24.31 | 0.02 | +0.07% |
| State Street My2029 Corporate Bond ETF (MYCI) | |||
| TAXI | 50.51 | 0.01 | +0.02% |
| Northern Trust Intermediate Tax-Exempt Bond ETF (TAXI) | |||
| RKSG | 28.56 | N/A | N/A |
| Ruk Strategic Growth ETF (RKSG) | |||
| CET | 52.16 | -0.02 | -0.04% |
| Central Securities Corp | |||
| CUT | 26.90 | -0.60 | -2.18% |
| Invesco MSCI Global Timber ETF (CUT) | |||
A.I.dvisor indicates that over the last year, WW has been loosely correlated with AIRS. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if WW jumps, then AIRS could also see price increases.
a provider of weight management services
Industry HospitalNursingManagement
WW saw its Momentum Indicator move below the 0 level on November 03, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 84 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for WW turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 40 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for WW entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +18.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where WW advanced for three days, in 210 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
WW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.406) is normal, around the industry mean (204.532). P/E Ratio (0.827) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (5.307) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.167) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. WW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.